Seven Eight Capital LP Takes Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

Seven Eight Capital LP acquired a new position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 34,337 shares of the company’s stock, valued at approximately $1,348,000. Seven Eight Capital LP owned 0.07% of Structure Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the business. Wellington Management Group LLP boosted its holdings in Structure Therapeutics by 404.0% during the fourth quarter. Wellington Management Group LLP now owns 4,372,326 shares of the company’s stock valued at $178,216,000 after purchasing an additional 3,504,747 shares in the last quarter. Avoro Capital Advisors LLC boosted its stake in Structure Therapeutics by 133.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,333,333 shares of the company’s stock valued at $95,107,000 after buying an additional 1,333,333 shares in the last quarter. RA Capital Management L.P. grew its position in Structure Therapeutics by 210.2% in the first quarter. RA Capital Management L.P. now owns 1,510,362 shares of the company’s stock valued at $64,734,000 after acquiring an additional 1,023,530 shares during the period. Capital International Investors acquired a new position in Structure Therapeutics during the fourth quarter worth $34,647,000. Finally, Capital Research Global Investors lifted its holdings in shares of Structure Therapeutics by 182.3% during the fourth quarter. Capital Research Global Investors now owns 973,535 shares of the company’s stock valued at $39,681,000 after acquiring an additional 628,687 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Price Performance

Shares of Structure Therapeutics stock opened at $38.75 on Friday. The firm has a 50 day simple moving average of $38.01 and a 200 day simple moving average of $39.63. Structure Therapeutics Inc. has a fifty-two week low of $26.61 and a fifty-two week high of $75.02. The firm has a market cap of $1.81 billion, a P/E ratio of -50.32 and a beta of -3.52.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. On average, sell-side analysts expect that Structure Therapeutics Inc. will post -0.86 EPS for the current year.

Analysts Set New Price Targets

GPCR has been the subject of a number of recent analyst reports. BMO Capital Markets increased their target price on shares of Structure Therapeutics from $83.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, June 7th. JMP Securities cut their target price on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a research note on Friday, August 9th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a research report on Monday. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, Structure Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $84.63.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.